TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19174306

Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study: 17587087

Group type: EXPERIMENTAL
Intervention: Starion hemorrhoidectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Ligasure hemorrhoidectomy
Number of subjects: 64
Study: 15253170

Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system fentanyl (TTS-F)
Number of subjects: 0
Study: 12435175

Group type: EXPERIMENTAL
Intervention: Capecitabine and docetaxel combination treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-agent docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poststudy treatment with capecitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment (capecitabine/docetaxel)
Number of subjects: 0
Study: 9825366

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 8110697

Group type: EXPERIMENTAL
Intervention: Sustained release acetazolamide (500 mg twice a day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2114627

Group type: EXPERIMENTAL
Intervention: recombinant IFN‐gamma (100 micrograms each)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 113143

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg orally followed by TRH intravenously
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.5 mg orally followed by placebo injection
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo tablet followed by TRH intravenously
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo tablet followed by placebo injection
Number of subjects: 6
Study: 31229376

Group type: EXPERIMENTAL
Intervention: HREZ (HRE + Pyrazinamide)
Number of subjects: 89

Group type: COMPARATOR
Intervention: HRE (Isoniazid, Rifampicin, Ethambutol)
Number of subjects: 89
Study: 27834619

Group type: EXPERIMENTAL
Intervention: Low-dose plyometric training (PT), 60 foot contacts, twice-weekly for 6 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-dose plyometric training (PT) in Mid-PHV group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Low-dose plyometric training (PT) in Pre-PHV group
Number of subjects: 38
Study: 25576320

Group type: EXPERIMENTAL
Intervention: In vitro fertilisation with single embryo transfer
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: In vitro fertilisation in a modified natural cycle
Number of subjects: 602

Group type: COMPARATOR
Intervention: Intrauterine insemination with controlled ovarian hyperstimulation
Number of subjects: 602
Study: 23470915

Group type: EXPERIMENTAL
Intervention: Endurance training + normal heat (ET+NH)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Endurance training + moderate heat (ET+MH)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weight training + normal heat (WT+NH)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weight training + moderate heat (WT+MH)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Heat group (HG)
Number of subjects: 45
Study: 20623240

Group type: EXPERIMENTAL
Intervention: Fundus-down laparoscopic cholecystectomy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy
Number of subjects: 64
Study: 19443665

Group type: EXPERIMENTAL
Intervention: Chimney woodstove (plancha)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Open fire (control)
Number of subjects: 504
Study: 17163102

Group type: EXPERIMENTAL
Intervention: EVAR (Endovascular Aneurysm Repair)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EVAR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open AAA repair
Number of subjects: 0
Study: 15049856

Group type: EXPERIMENTAL
Intervention: 35% CO(2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 5% CO(2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 25% CO(2)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 50% CO(2)
Number of subjects: 9
Study: 11722314

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT), 10 sessions including cognitive methods, behavioural methods, problem-solving skills training, and behavioural counselling to significant others.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine medical treatment (Control group)
Number of subjects: 40
Study: 9393272

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy including breathing with pursed lips, huffing and coughing, and resistance training on inspiration and expiration with a mask (inspiration -5 cmH2O, expiration +10 cmH2O)
Number of subjects: 368

Group type: COMPARATOR
Intervention: No treatment or information provided to the control group
Number of subjects: 368
Study: 8192413

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 40

Group type: COMPARATOR
Intervention: No fibrin glue (control)
Number of subjects: 40
Study: 3259337

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg/kg)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Thiopental (4.0 mg/kg)
Number of subjects: 62
Study: 28493407

Group type: EXPERIMENTAL
Intervention: First-person perspective video prior to simulation training
Number of subjects: 40

Group type: COMPARATOR
Intervention: No video prior to simulation training
Number of subjects: 40
Study: 28453780

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2806

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2806
Study: 26183034

Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy (GDFT) with the LiDCOrapid system
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine fluid therapy (Control)
Number of subjects: 100
Study: 23604798

Group type: EXPERIMENTAL
Intervention: Deep Squat (DS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Shallow Squat (SS)
Number of subjects: 17
Study: 20006169

Group type: EXPERIMENTAL
Intervention: Thermosetting gel containing 2.5% prilocaine and 2.5% lidocaine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Eugenol on a gauze strip
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Thermosetting gel
Number of subjects: 35

Group type: COMPARATOR
Intervention: Eugenol
Number of subjects: 35
Study: 18472381

Group type: EXPERIMENTAL
Intervention: Rupatadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Estazolam (internal standard)
Number of subjects: 0
Study: 15895850

Group type: EXPERIMENTAL
Intervention: 1 lift/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 lifts/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 4 lifts/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 70 x 35 x 15 cm
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 50 x 50 x 15 cm
Number of subjects: 10
Study: 14559418

Group type: EXPERIMENTAL
Intervention: Solid (filled) pictorials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pictorials 75% size of inner diameter of circle‐slash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pictorials with greater vertical DE (tall/thin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diagonal slashes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thickness of red circle‐slash comprising 25% of total area inside outer circle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thicker slash and smaller pictorial size
Number of subjects: 0
Study: 9874712

Group type: EXPERIMENTAL
Intervention: Low-dose thalidomide (200 mg, escalated to 1200 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-dose thalidomide (200 mg, escalated to 1200 mg)
Number of subjects: 45
Study: 8911877

Group type: EXPERIMENTAL
Intervention: Flosequinan (100 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1806811

Group type: EXPERIMENTAL
Intervention: Oral DDAVP (150 to 600 micrograms/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Intranasal DDAVP
Number of subjects: 13
Study: 6441815

Group type: EXPERIMENTAL
Intervention: Prostaglandin synthetase promoter (263E) 500 mg three times daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg at night
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31577678

Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics for 24 hours
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics for 72 hours
Number of subjects: 552
Study: 27684541

Group type: EXPERIMENTAL
Intervention: Modified dot-probe protocol (active)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard dot-probe protocol (control)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both protocols (modified and standard)
Number of subjects: 113
Study: 27354766

Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate (MgSO4)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate (MgSO4) and salbutamol combination
Number of subjects: 30
Study: 24381294

Group type: EXPERIMENTAL
Intervention: fMRI decoding of spoken words in one language (e.g., 'horse' in English)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fMRI response patterns discriminative of spoken words within language
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: fMRI response patterns discriminative of spoken words across language
Number of subjects: 0
Study: 21706151

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) add-on to riluzole, initial dose of 2 IU s.c. every other day, progressively increased to a maximum of 8 IU.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) add-on to riluzole
Number of subjects: 0
Study: 21203523

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted H5 VLP vaccine (5, 10, or 20 µg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (alum)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted H5 VLP vaccine (10 or 20 µg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted H5 VLP vaccine (all doses)
Number of subjects: 0
Study: 17882705

Group type: EXPERIMENTAL
Intervention: Topical dexamethasone eyedrops
Number of subjects: 285

Group type: COMPARATOR
Intervention: Diclofenac drops
Number of subjects: 285
Study: 16392974

Group type: EXPERIMENTAL
Intervention: ST with vouchers
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: ST with prizes
Number of subjects: 142

Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: ST with vouchers and ST with prizes
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Longest duration of abstinence achieved during treatment
Number of subjects: 142
Study: 12020141

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention program (11-week duration) including education, environmental modifications, exercise programs, drug regimen reviews, provision of hip protectors, and post-fall conferences.
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 439
Study: 9861554

Group type: EXPERIMENTAL
Intervention: Positive expectancy outcome condition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Negative expectancy outcome condition
Number of subjects: 64

Group type: COMPARATOR
Intervention: Neutral (control) condition
Number of subjects: 64
Study: 8570882

Group type: EXPERIMENTAL
Intervention: Low-dose ofloxacin (OFLX) and erythromycin (EM) therapy daily for 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent treatment of OFLX and EM therapy for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycin (EM) therapy for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (neither OFLX nor EM therapy)
Number of subjects: 0
Study: 2195006

Group type: EXPERIMENTAL
Intervention: Clomipramine (N = 16)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (N = 16)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 32
Study: 386492

Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 30173058

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) or Acceptance and Commitment Therapy (ACT)
Number of subjects: 34
Study: 28178175

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 40
Study: 25261005

Group type: EXPERIMENTAL
Intervention: Helicopter-based ALS rescue concept with in-water ventilation and chest compressions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calm water conditions
Number of subjects: 0
Study: 23107590

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + folinic acid (FA)
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + interferon‐alfa (IFN‐alfa)
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + folinic acid (FA) in stage II RC
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU) + folinic acid (FA) in stage III RC
Number of subjects: 1651

Group type: EXPERIMENTAL
Intervention: Lung metastases
Number of subjects: 1651
Study: 21434340

Group type: EXPERIMENTAL
Intervention: Chaipo Granule (CPG) 3 pouches twice a day for 24 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine treatment (salmeterol and fluticasone propionate, salbutamol + ipratropium bromide)
Number of subjects: 60
Study: 19842560

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (2‐4 U/h)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine therapy (no insulin administration)
Number of subjects: 80
Study: 16996827

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD) therapy
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 700
Study: 14593127

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (including percutaneous transluminal angioplasty, balloon-expandable stent, self-expandable stent)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 104
Study: 10924782

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/B vaccine (Twinrix Adult)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Monovalent vaccines (Havrix 1440+Engerix‐B or Vaqta+Gen H‐B‐Vax)
Number of subjects: 5
Study: 8936360

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1583173

Group type: EXPERIMENTAL
Intervention: Calcipotriol (50 micrograms/gm) ointment
Number of subjects: 409

Group type: COMPARATOR
Intervention: Betamethasone 17-valerate (1 mg/gm) ointment
Number of subjects: 409
Study: 2931148

Group type: EXPERIMENTAL
Intervention: fenoterol
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 96

Group type: COMPARATOR
Intervention: FEV1
Number of subjects: 96
Study: 31474193

Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 47
Study: 30513818

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Lifestyle counseling
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both interventions (Liraglutide and Lifestyle counseling)
Number of subjects: 35
Study: 26656041

Group type: EXPERIMENTAL
Intervention: Thrust spinal manipulation (SM)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Nonthrust spinal manipulation (SM)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 192
Study: 25475247

Group type: EXPERIMENTAL
Intervention: Integrative medicine rehabilitation (IMR) group receiving acupuncture and Chinese herbs in addition to basic Western medicine and rehabilitation treatment.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR) group not receiving acupuncture and Chinese herbal medicine.
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Integrative medicine rehabilitation (IMR) group
Number of subjects: 360

Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR) group
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 360
Study: 22116310

Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training (RET)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Training (AET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait List (WL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combined exercise conditions (RET and AET)
Number of subjects: 30
Study: 20823897

Group type: EXPERIMENTAL
Intervention: Folinic acid (5‐formyltetrahydrofolate) at a dosage of 70 μg/kg/day for 2 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no folinic acid treatment)
Number of subjects: 37
Study: 18257178

Group type: EXPERIMENTAL
Intervention: Abdominal electroacupuncture (EA) at Daheng (SP 15), Fujie (SP 14), Tianshu (ST 25), Shuidao (ST 28), once a day for 30 minutes.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cisapride, 10 mg orally, three times a day.
Number of subjects: 80
Study: 15694243

Group type: EXPERIMENTAL
Intervention: Psychotropic drugs
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no drug exposure)
Number of subjects: 124
Study: 15570143

Group type: EXPERIMENTAL
Intervention: Historical Physical Activity Questionnaire (HPAQ) recall
Number of subjects: 163

Group type: COMPARATOR
Intervention: Original Physical Activity Questionnaires (1982, 1985, 1995, 1999)
Number of subjects: 163
Study: 11390725

Group type: EXPERIMENTAL
Intervention: AN‐69 group (n=13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: CELL group (n=11)
Number of subjects: 24
Study: 9223023

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, qid) in REFLUX-group (N = 43)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg, tid) in REFLUX-group (N = 43)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, qid) in DYSPEPSIA-group (N = 84)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Domperidone (20 mg, tid) in DYSPEPSIA-group (N = 84)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both therapies (Cisapride and Domperidone)
Number of subjects: 127
Study: 8354325

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) 5 mg, inhaled four times a day for 3 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo, inhaled four times a day for 3 weeks
Number of subjects: 16
Study: 3814542

Group type: EXPERIMENTAL
Intervention: 50 Hz electric currents (500 microamperes)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 76
Study: 31495952

Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg teduglutide
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg teduglutide
Number of subjects: 59

Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 59
Study: 28901811

Group type: EXPERIMENTAL
Intervention: Horizontal adduction stretch
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Supine sleeper stretch
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (no stretch)
Number of subjects: 63
Study: 27852236

Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 200 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both FCM and IS
Number of subjects: 42
Study: 25022782

Group type: EXPERIMENTAL
Intervention: Anticipatory processing task
Number of subjects: 59

Group type: COMPARATOR
Intervention: Distraction task
Number of subjects: 59
Study: 22285177

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 23
Study: 20688319

Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Imaginal processing
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 61
Study: 18853555

Group type: EXPERIMENTAL
Intervention: Aligned attractive bottom halves of faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misaligned and upside-down presentations of faces
Number of subjects: 0
Study: 16632570

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate/electrolyte drink (CHO‐E)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water
Number of subjects: 14
Study: 14643741

Group type: EXPERIMENTAL
Intervention: Direct victimization at school by peers
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Direct victimization at home by parents
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Vicarious victimization (exposure to domestic violence)
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Gender and age as predictors
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Relational victimization at school
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Direct victimization at home by the father (for boys) and by both parents (for girls)
Number of subjects: 998
Study: 11177199

Group type: EXPERIMENTAL
Intervention: HIFAT (1.2 g saturated fat/kg BM with 3500 U heparin intravenously)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: CHO (2.5 g carbohydrate/kg BM)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: NA (2.5 g carbohydrate + 20 mg nicotinic acid/kg BM)
Number of subjects: 7

Group type: COMPARATOR
Intervention: HIFAT
Number of subjects: 7

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 7
Study: 8994707

Group type: EXPERIMENTAL
Intervention: Primary stent placement (n = 107)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Primary PTA (n = 106)
Number of subjects: 213

Group type: COMPARATOR
Intervention: PTA plus selective stent placement
Number of subjects: 213
Study: 1482131

Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (beta-lactam plus aminoglycoside)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Monotherapy (beta-lactam or aminoglycoside)
Number of subjects: 230